nabumetone has been researched along with Rheumatism in 11 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) used to treat rheumatic and inflammatory conditions." | 5.29 | Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. ( Buckley, MM; Friedel, HA; Langtry, HD, 1993) |
| "We evaluated the clinical efficacy and the tolerance of Nabumetone (N), in comparison with a pool of non-steroidal anti-inflammatory drugs (NSAIDs), in a cohort of patients affected by rheumatoid arthritis, osteoarthritis, non-articular rheumatisms and primary fibromyalgic syndrome." | 5.08 | Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment. ( Allegra, A; Coaccioli, S; Di Cato, L; Puxeddu, A, 1998) |
| "Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthylalkanone class." | 2.41 | [Properties and features of nabumetone]. ( Davies, NM; McLachlan, AJ, 2000) |
| " The excellent tolerability of nabumetone and its 24-hour half-life, which provides the advantages of a once-daily dosage regimen, make it uniquely suitable for long term anti-inflammatory therapy in arthritis." | 2.41 | [Rationale for using nabumetone and clinical experience]. ( Roth, SH, 2000) |
| "Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) used to treat rheumatic and inflammatory conditions." | 1.29 | Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. ( Buckley, MM; Friedel, HA; Langtry, HD, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lennerz, JK | 1 |
| Lauwers, GY | 1 |
| Friedel, HA | 1 |
| Langtry, HD | 1 |
| Buckley, MM | 1 |
| Giordano, N | 1 |
| Senesi, M | 1 |
| Battisti, E | 1 |
| Gonnelli, S | 1 |
| Franci, B | 1 |
| Campagna, MS | 1 |
| Mattii, G | 1 |
| Palumbo, F | 1 |
| Gennari, C | 1 |
| Coaccioli, S | 1 |
| Allegra, A | 1 |
| Di Cato, L | 1 |
| Puxeddu, A | 1 |
| Davies, NM | 1 |
| McLachlan, AJ | 1 |
| Roth, SH | 1 |
| Bianchi Porro, G | 1 |
| Petrillo, M | 1 |
| Ardizzone, S | 1 |
| Caruso, I | 1 |
| Montone, F | 1 |
| Stroehmann, I | 2 |
| Giersch, KH | 1 |
| Zeidler, H | 1 |
| Münzel, P | 2 |
| Lemmel, EE | 1 |
| Lemmel, EM | 1 |
3 reviews available for nabumetone and Rheumatism
| Article | Year |
|---|---|
[Properties and features of nabumetone].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Rheumatic Diseases | 2000 |
[Rationale for using nabumetone and clinical experience].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Rheumatic Diseases | 2000 |
Gastroscopic evaluation of the effects of nabumetone on the gastrointestinal mucosa of rheumatic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Controlled Clinical Trials as Topic; Digestive S | 1991 |
3 trials available for nabumetone and Rheumatism
| Article | Year |
|---|---|
Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Female; Huma | 1998 |
Efficacy and safety of nabumetone in patients with rheumatic diseases. Results of an outpatient study involving 8,865 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose | 1990 |
Efficacy and safety of nabumetone in 4,541 elderly patients from a drug monitoring study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Drug Evaluation; Female; Humans; Male; Nab | 1990 |
5 other studies available for nabumetone and Rheumatism
| Article | Year |
|---|---|
Amelanotic adenoma.
Topics: Adenoma; Butanones; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Humans; Ibuprofen; Intes | 2013 |
Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastric Mucosa; Hemodynamics; Humans; N | 1993 |
Tolerability of nabumetone: a pilot in vitro study showing absence of injury to articular cartilage.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cartilage, Articular; Case-Control Studie | 1996 |
[Arthaxan--perspectives and alternatives in rheumatic therapy!].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Rheumatic Diseases | 1989 |
[Treatment of rheumatic diseases with nabumetone. Results of a study using the drug in 18,046 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 1988 |